HC Wainwright Issues Pessimistic Estimate for GENB Earnings

Generate Biomedicines Inc (NASDAQ:GENB – Free Report) – Research analysts at HC Wainwright cut their FY2026 earnings estimates for Generate Biomedicines in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($2.46) per share for the year, down from their previous estimate of ($2.16). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Generate Biomedicines’ current full-year earnings is ($2.46) per share. HC Wainwright also issued estimates for Generate Biomedicines’ Q4 2026 earnings at ($0.69) EPS, Q1 2027 earnings at ($0.71) EPS, Q2 2027 earnings at ($0.63) EPS, Q3 2027 earnings at ($0.63) EPS, Q4 2027 earnings at ($0.63) EPS and FY2027 earnings at ($2.60) EPS.

Generate Biomedicines (NASDAQ:GENB – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.18). The firm had revenue of $4.22 million during the quarter. Generate Biomedicines had a negative net margin of 1,289.97% and a negative return on equity of 151.21%.

Several other equities research analysts have also commented on the stock. Wall Street Zen lowered shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. Morgan Stanley reduced their price objective on Generate Biomedicines from $22.00 to $21.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Weiss Ratings lowered Generate Biomedicines from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $26.20.

Get Our Latest Report on GENB

Generate Biomedicines Stock Up 5.5%

Generate Biomedicines stock opened at $10.38 on Tuesday. Generate Biomedicines has a 52-week low of $9.68 and a 52-week high of $22.67. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.01 and a quick ratio of 5.01. The firm has a 50-day moving average price of $14.01 and a two-hundred day moving average price of $14.04.

Institutional Investors Weigh In On Generate Biomedicines

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. New York State Common Retirement Fund acquired a new stake in Generate Biomedicines in the third quarter worth about $129,000. Susquehanna International Group LLP acquired a new position in Generate Biomedicines during the 2nd quarter valued at about $196,000. AXQ Capital LP acquired a new position in Generate Biomedicines during the 2nd quarter valued at about $218,000. Summa Corp. acquired a new position in Generate Biomedicines during the 3rd quarter valued at about $250,000. Finally, Magnus Financial Group LLC raised its position in shares of Generate Biomedicines by 39.4% during the 3rd quarter. Magnus Financial Group LLC now owns 21,750 shares of the company’s stock worth $327,000 after buying an additional 6,150 shares in the last quarter.

Recent Generate Biomedicines Headlines

Here are a few of the latest headlines about GENB:

  • Positive Sentiment: Morgan Stanley cut its price target to $21 from $22 but maintained an Overweight rating. At the cited share price of $10.38, the revised target still implies substantial upside, which may support investor sentiment. Morgan Stanley ratings
  • Negative Sentiment: HC Wainwright lowered its EPS forecasts for Q4 2026, each quarter of 2027, and full-year 2026 and 2027. Its FY2027 loss estimate widened to $2.60 per share from $2.09, indicating expectations for deeper losses. The analyst nevertheless kept a Buy rating. Generate Biomedicines analyst estimates

Generate Biomedicines Company Profile

(Get Free Report)

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts. Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma.

Recommended Stories

Earnings History and Estimates for Generate Biomedicines (NASDAQ:GENB)

Receive News & Ratings for Generate Biomedicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generate Biomedicines and related companies with MarketBeat.com's FREE daily email newsletter.